Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.39 |
---|---|
High | 6.39 |
Low | 6.39 |
Bid | 6.46 |
Offer | 6.59 |
Previous close | 6.33 |
Average volume | 77.78 |
---|---|
Shares outstanding | 275.00m |
Free float | 269.88m |
P/E (TTM) | 195.71 |
Market cap | 1.93bn USD |
EPS (TTM) | 0.0359 USD |
Data delayed at least 15 minutes, as of Oct 31 2024 07:08 BST.
More ▼
- MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
- More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)
- MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
- MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
- MannKind to Present at Upcoming Conferences
- Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board
- MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update
- MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease
- MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024
- INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
More ▼